跳到正文
Targeted Oncology· @TargetedOnc · X·· 22 小时前评分70

KEYNOTE-B49

正文 · 原文

Could PD-L1 selection be the real story in KEYNOTE-B49?

In CPS ≥10, PFS HR was 0.59 (median 7.5 vs 4.4 months).

Is this a clinically meaningful subgroup or an exploratory signal?

We need interaction testing, subgroup OS and patient-reported outcomes. #ESMO26

64 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)

https://esmocongress.esmo.org

来源:Targeted Oncology · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org